Search - tctmd.com

Displaying 1 - 20 of 21

Sort: Relevancy | Date

What’s Going to Be Hot at TCT 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

News Conference News ESC 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

September 05, 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

March 29, 2025

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

News Daily News

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

Yael L. Maxwell

June 26, 2024

Benefits of 12-Month DAPT After CABG Persist to 5 Years: DACAB

News Daily News

Benefits of 12-Month DAPT After CABG Persist to 5 Years: DACAB

Yael L. Maxwell

June 14, 2024

After COVID-19, Unvaccinated at Risk for Long-term CVD Complications

News Daily News

After COVID-19, Unvaccinated at Risk for Long-term CVD Complications

Michael O'Riordan

August 16, 2022

The Right Anticoagulation Dose in COVID-19? Final Answer Remains Elusive

News Features

The Right Anticoagulation Dose in COVID-19? Final Answer Remains Elusive

February 08, 2021

Antithrombotics After PFO Closure: Much to Discuss, Little Data to Inform

News Conference News TVT 2020

Antithrombotics After PFO Closure: Much to Discuss, Little Data to Inform

Yael L. Maxwell

June 26, 2020

TICONC: Ticagrelor May Cut Tumor-Induced Platelet Aggregation in Cancer Patients

News Daily News

TICONC: Ticagrelor May Cut Tumor-Induced Platelet Aggregation in Cancer Patients

June 17, 2020

News Daily News

FDA Approves Two Generic Versions of Apixaban

December 23, 2019

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

News Conference News AHA 2018

Rivaroxaban Lowers Thromboembolic Risk in HF Patients: COMMANDER HF

November 11, 2018

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

October 12, 2018

MANAGE Suggests Dabigatran Could Be Useful for Treating Myocardial Injury After Noncardiac Surgery

News Conference News ACC 2018

MANAGE Suggests Dabigatran Could Be Useful for Treating Myocardial Injury After Noncardiac Surgery

March 11, 2018

TCTMD’s Top 10 Most Popular Stories for December 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2017

December 28, 2017

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

September 15, 2017

Rivaroxaban’s “Overwhelming” Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

News Daily News

Rivaroxaban’s ‘Overwhelming’ Efficacy for Coronary, Peripheral Disease Leads to Early Halt of COMPASS

February 08, 2017

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Daily News

Bleeding Risk of Triple Therapy Not Attenuated by Well-Controlled Warfarin

August 30, 2013

News Conference News ACC 2012

Daily Rivaroxaban as Effective as Enoxaparin for Pulmonary Embolism

March 26, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.